35 research outputs found
A new mosaic der(18)t(1;18)(q32.1;q21.3) with developmental delay and facial dysmorphism
We report the case of a 22-month-old boy with a new mosaic partial unbalanced translocation of 1q and 18q. The patient was referred to our Pediatric Department for developmental delay. He showed mild facial dysmorphism, physical growth retardation, a hearing disability, and had a history of patent ductus arteriosus. White matter abnormality on brain magnetic resonance images was also noted. His initial routine chromosomal analysis revealed a normal 46,XY karyotype. In a microarray-based comparative genomic hybridization (aCGH) analysis, subtle copy number changes in 1q32.1โq44 (copy gain) and 18q21.33โ18q23 (copy loss) suggested an unbalanced translocation of t(1;18). Repeated chromosomal analysis revealed a low-level mosaic translocation karyotype of 46,XY,der(18)t(1;18)(q32.1;q21.3)[12]/46,XY[152]. Because his parents had normal karyotypes, his translocation was considered to be de novo. The abnormalities observed in aCGH were confirmed by metaphase fluorescent in situ hybridization. We report this patient as a new karyotype presenting developmental delay, facial dysmorphism, cerebral dysmyelination, and other abnormalities
Predictive Value of Post-Transplant Bone Marrow Plasma Cell Percent in Multiple Myeloma Patients Undergone Autologous Transplantation
Immunocytes as a Biocarrier to Delivery Therapeutic and Imaging Contrast Agents to Tumors
Radiotherapy for cancer treatment has been used for primary or adjuvant treatment in many types of cancer, and approximately half of all cancer patients are undergoing radiation. However, ionizing radiation exposure induces genetic alterations in cancer cells and results in recruitment of monocytes/macrophages by triggering signals released from these cells. Using this characteristic of monocytes/macrophages, we have attempted to develop a biocarrier loading radiosensitizing anticancer agents that can lead to enhance the therapeutic effect of radiation in cancer treatment. The aim of this study is to demonstrate the proof of this concept. THP-1 labeled with Qdot 800 or iron oxide (IO) effectively migrated into tumors of subcutaneous mouse model and increased recruitment after ionizing radiation. Functionalized liposomes carrying a radiosensitizing anticancer agent, doxorubicin, are successfully loaded in THP-1 (THP-1-LP-Dox) with reduced cytotoxicity, and THP-1-LP-Dox also was observed in tumors after intravenous administration. Here, we report that monocytes/macrophages as a biocarrier can be used as a selective tool for amplification of the therapeutic effects on radiotherapy for human cancer treatment
Flexible CFD meshing strategy for prediction of ship resistance and propulsion performance
The safety and efficacy of haemostasis with a catechol-conjugated, chitosan-based haemostatic dressing versus a chitosan-based haemostatic dressing after transfemoral approach for transcatheter arterial chemoembolization : a randomized controlled trial
Purpose: To compare the haemostatic efficacy (i.e. efficacy to prevent access site complications) of the InnoSEAL haemostatic pad and Clo-Sur PLUS P.A.D. after femoral arterial puncture for transcatheter arterial chemoembolization (TACE). Material and methods: This randomized controlled trial compared the safety and efficacy of an InnoSEAL haemostatic pad (n = 48) and a Clo-Sur PLUS P.A.D. (n = 52) for haemostasis of arterial puncture sites after TACE with femoral arterial access using a 5-Fr sheath. Primary endpoints were incidence of major (necessitating surgery) and moderate access site complications (ASC) (necessitating blood transfusion/thrombin injection). Secondary endpoints were incidence of minor ASC (no therapy required) and time to haemostasis. Results: No major or moderate ASC was seen with either device. Minor ASC (6.3% [3/48] vs. 19.2% [10/52], p = 0.075) and ecchymosis (classified as minor ASC; 4.2% [2/48] vs. 17.3% [9/52]; p = 0.053, p-value cut-off after Bonferroni correction = 0.025) were less frequently observed with the InnoSEAL haemostatic pad. The time to haemostasis did not differ significantly between the 2 devices (5.6 ยฑ 1.0 vs. 5.3 ยฑ 0.7 minutes; p = 0.118). Multivariable logistic regression analysis showed a lower risk of ASC with the InnoSEAL pad (adjusted OR, 0.174; 95% CI: 0.034-0.890; p = 0.036). Conclusions: No major ASC was seen with either pad, and no significant difference of minor ASC was observed between 2 pads
Flexible CFD meshing strategy for prediction of ship resistance and propulsion performance
Transforming growth factor conjugated chitosan film for enhanced osteoblastic activity
๊ณจ์์ธํฌ์ ์๋ฌผํ์ ๊ธฐ๋ฅ์ ์ฆ์ง์ํค๊ธฐ ์ํด ํคํ ์ฐ์ ํ๋ฉด๊ฐ์ง์ ๋ํ์ฌ ์ฐ๊ตฌํ์๋ค. ์์ฒด์ ํฉ์ฑ ์ฒ์ฐ๊ณ ๋ถ์์ธ ํคํ ์ฐ์ 1์ฐจ ์๋ฏธ๋
ธ๊ธฐ๋ฅผ ์์ ํ๊ณ ์์ผ๋ฏ๋ก ์ ์ ํ ๊ณต์ ๊ฒฐํฉ์ ๋ฅผ ์ฌ์ฉํ์ฌ ์ธํฌ์ฑ์ฅ์ธ์์ ๊ฐ์ ์๋ฆฌํ์ฑ์ ์ง๋ ๋จ๋ฐฑ์ง์ ํคํ ์ฐ์ ํ๋ฉด์ ๊ณ ์ ์ํฌ ์ ์๋ค. ๋ณธ ์ฐ๊ตฌ์์๋ ํคํ ์ฐ์ ํ๋ฆํํ๋ก ์ ์กฐํ์ฌ ์ธํฌ์ฑ์ฅ์ธ์ ์ค ํ์ง์ ํ์ฑ์ฅ์ธ์๋ฅผ ๊ณ ์ ํ๊ณ ๊ณจ์์ธํฌ์ ๋ถ์ฐฉ, ์ฑ์ฅ ๋ฐ ๋ถํ๋ฅผ ์ฆ๊ฐ์ํค๊ณ ์ ํ์๋ค. ํํ์ ํ์ฑ์ฅ์ธ์์ ๊ณ ์ ํ ํจ์จ์ ๋จ์ํ ํก์ฐฉ๋ฐฉ๋ฒ์ ๋นํด ๋์์ผ๋ฉฐ, ํ๋ฉด์ ํ์ฑ๋ ๊ณต์ ๊ฒฐํฉ์ ๋งค์ฐ ์์ ํ์๋ค. ๊ณจ์์ธํฌ๋ฅผ ๋ฐฐ์ํ์ฌ ์ด๊ธฐ์ธํฌ๋ถ์ฐฉ๋ฅ์ ๋ํ ์ํฅ์ ์ฐ๊ตฌํ ๊ฒฐ๊ณผ, ๋ฐฐ์ ํ 4์๊ฐ, 1์ผ์งธ, ํ์ง์ ํ์ฑ์ฅ์ธ์๋ฅผ ๊ณ ์ ํ ํคํ ์ฐ ํ๋ฉด์์ ๊ณ ์ ํ์ง ์์ ํคํ ์ฐ์ ํ๋ฉด์ ๋นํด ๋ ๋ง์ ์์ ๊ณจ์์ธํฌ๊ฐ ๋ถ์ฐฉ๋์๊ณ , ๋ ๋ง์ด ์ ์ฅ๋ ๋ถ์ฐฉํํ๋ฅผ ๋ณด์๋ค. ์ธํฌํ์ฑ์ ๋์ ๋ฐฐ์ ํ 4์ฃผ์ผ์งธ์ ์นผ์์ถ์ ๋์ ์ธก์ ํ ๊ฒฐ๊ณผ, ํ์ง์ ํ์ฑ์ฅ์ธ์๋ฅผ ๊ณ ์ ํ ํคํ ์ฐ ํ๋ฉด์์ ๊ณ ์ ํ์ง ์์ ํคํ ์ฐ์ ํ๋ฉด์ ๋นํด ๋ ๋์๋ค. ์์ ๊ฒฐ๊ณผ๋ ํคํ ์ฐ ํ๋ฉด์ ํํ์ ํ์ฑ์ฅ์ธ์์ ๊ณ ์ ์ด ์ฑ๊ณต์ ์ผ๋ก ์ด๋ฃจ์ด์ก์ผ๋ฉฐ, ๋ํ ์ค์ ๋ก ํ์ฑ์ด ์๋ ๊ฒ์ด ์ฆ๋ช
๋์๋ค. ์์ ์ฐ๊ตฌ ๊ฒฐ๊ณผ์์ ํ์ง์ ํ์ฑ์ฅ์ธ์๋ก ๊ณ ์ ๋ ํคํ ์ฐ์ ๊ณจ์์ธํฌ์ ์ด๊ธฐ ๋ถ์ฐฉ ๋ฐ ๋ถํ๋ฅผ ์ด์ง์์ผฐ์์ ์ ์ ์์๋ ๋ฐ ์ฑ์ฅ์ธ์์ ํ๋ฉด๊ณ ์ ์ ์ํ๋ํธ ๋ฐ ์กฐ์ง๊ณตํ์ฉ ์ง์ง์ฒด์๋ ์ ์ฉํ์ฌ ์์ฒด์ ํฉ์ฑ๊ณผ ์ธํฌ๊ธฐ๋ฅ์ ์ฆ์ง์ํค๋๋ฐ ์ด์ฉํ ์ ์์์ ์ ์ ์์